Business Description
Monte Rosa Therapeutics is a Boston-based clinical-stage biotech company focused on developing small molecule drugs that harness the body's own protein disposal system to eliminate disease-causing proteins. Its lead drug candidates target cancer driven by the MYC gene, autoimmune and inflammatory conditions, and several other serious diseases. The company uses a proprietary discovery platform called QuEEN to design and advance these treatments, and works in partnership with Roche and Novartis to support its research and development efforts.
